Feasibility of Neoadjuvant Immune Checkpoint Blockade for Resectable Diffuse Pleural Mesothelioma Along Potential of ctDNA Analyses to Detect Residual Disease By Ogkologos - September 22, 2025 322 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a phase II study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Kids Facing Difficult Medical Diagnoses Take Train To The ‘North Pole’... December 12, 2021 What Survivors Should Know When Transitioning From Cancer Care to Primary... April 4, 2023 People with Intellectual Disability at Increased Risk of Cancer September 21, 2021 New on NCI’s Websites for March 2021 March 25, 2021 Load more HOT NEWS Efficacy of Talquetamab Plus Teclistamab in Patients with Extramedullary Myeloma ESMO Gynaecological Cancers Congress 2023 New study to investigate breast cancer in ethnic minority groups GreaterGood Partners with Organization of Hope to Deliver Toys and Necessities...
